Health care stocks leaned lower premarket Thursday with the Health Care Select Sector SPDR Fund (XLV) declining by 0.9% and the iShares Biotechnology ETF (IBB) recently down 1.7%.
Keros Therapeutics (KROS) shares advanced by more than 14% after the company said its board has decided to initiate a formal review process to evaluate strategic alternatives.